Sagimet Biosciences announces positive topline results from phase 2b trial of denifanstat
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
Automated parallel capillary electrophoresis system simplifies protein analysis
The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others
Argo will receive upfront payments of US$ 185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.
This investment will be made by Caplin Point Laboratories Limited and its subsidiaries - Caplin Steriles Limited and Caplin One Labs Limited
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
Comprehensive clinical development programs being initiated for each investigational candidate
The clearance of this audit marks the successful registration of 8 APIs with CADIFA
Subscribe To Our Newsletter & Stay Updated